These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

356 related items for PubMed ID: 14642400

  • 1. Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives.
    Chapman MJ.
    Atherosclerosis; 2003 Nov; 171(1):1-13. PubMed ID: 14642400
    [Abstract] [Full Text] [Related]

  • 2. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW.
    Am J Cardiovasc Drugs; 2005 Nov; 5(6):379-87. PubMed ID: 16259526
    [Abstract] [Full Text] [Related]

  • 3. [Diabetic dyslipidaemia and the atherosclerosis].
    Márk L, Dani G.
    Orv Hetil; 2016 May 08; 157(19):746-52. PubMed ID: 27133274
    [Abstract] [Full Text] [Related]

  • 4. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
    Tenenbaum A, Fisman EZ, Motro M, Adler Y.
    Adv Cardiol; 2008 May 08; 45():127-153. PubMed ID: 18230960
    [Abstract] [Full Text] [Related]

  • 5. Fibrates, dyslipoproteinaemia and cardiovascular disease.
    Watts GF, Dimmitt SB.
    Curr Opin Lipidol; 1999 Dec 08; 10(6):561-74. PubMed ID: 10680050
    [Abstract] [Full Text] [Related]

  • 6. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ, Watson KE, Talbert RL.
    J Manag Care Pharm; 2008 Oct 08; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [Abstract] [Full Text] [Related]

  • 7. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ.
    Atheroscler Suppl; 2011 Nov 08; 12(3):277-84. PubMed ID: 22152282
    [Abstract] [Full Text] [Related]

  • 8. Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus.
    Keating GM, Croom KF.
    Drugs; 2007 Nov 08; 67(1):121-53. PubMed ID: 17209672
    [Abstract] [Full Text] [Related]

  • 9. Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages.
    Milosavljevic D, Griglio S, Le Naour G, Chapman MJ.
    Atherosclerosis; 2001 Mar 08; 155(1):251-60. PubMed ID: 11223449
    [Abstract] [Full Text] [Related]

  • 10. Management of dyslipidemia in patients with metabolic syndrome.
    Cziraky MJ.
    J Am Pharm Assoc (2003); 2004 Mar 08; 44(4):478-88; quiz 489-90. PubMed ID: 15372869
    [Abstract] [Full Text] [Related]

  • 11. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk.
    Chapman MJ, Redfern JS, McGovern ME, Giral P.
    Pharmacol Ther; 2010 Jun 08; 126(3):314-45. PubMed ID: 20153365
    [Abstract] [Full Text] [Related]

  • 12. Management of dyslipidemia in the metabolic syndrome: recommendations of the Spanish HDL-Forum.
    Ascaso J, Gonzalez Santos P, Hernandez Mijares A, Mangas Rojas A, Masana L, Millan J, Pallardo LF, Pedro-Botet J, Perez Jimenez F, Pintó X, Plaza I, Rubiés J, Zúñiga M.
    Am J Cardiovasc Drugs; 2007 Jun 08; 7(1):39-58. PubMed ID: 17355165
    [Abstract] [Full Text] [Related]

  • 13. Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome.
    Vega GL, Ma PT, Cater NB, Filipchuk N, Meguro S, Garcia-Garcia AB, Grundy SM.
    Am J Cardiol; 2003 Apr 15; 91(8):956-60. PubMed ID: 12686335
    [Abstract] [Full Text] [Related]

  • 14. The role of fibrate treatment in dyslipidemia: an overview.
    Katsiki N, Nikolic D, Montalto G, Banach M, Mikhailidis DP, Rizzo M.
    Curr Pharm Des; 2013 Apr 15; 19(17):3124-31. PubMed ID: 23317397
    [Abstract] [Full Text] [Related]

  • 15. [Hyperlipidemia and fibrates with special reference to diabetes].
    Henkel E, Hanefeld M.
    Herz; 2001 Dec 15; 26(8):523-30. PubMed ID: 11820155
    [Abstract] [Full Text] [Related]

  • 16. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
    Guerin M, Egger P, Soudant C, Le Goff W, van Tol A, Dupuis R, Chapman MJ.
    Atherosclerosis; 2002 Aug 15; 163(2):287-96. PubMed ID: 12052475
    [Abstract] [Full Text] [Related]

  • 17. Pharmacotherapy of mixed dyslipidemia in the metabolic syndrome.
    Nakajima K.
    Curr Clin Pharmacol; 2010 May 15; 5(2):133-9. PubMed ID: 20156152
    [Abstract] [Full Text] [Related]

  • 18. Diabetic dyslipidemia.
    Kreisberg RA.
    Am J Cardiol; 1998 Dec 17; 82(12A):67U-73U; discussion 85U-86U. PubMed ID: 9915665
    [Abstract] [Full Text] [Related]

  • 19. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia.
    Tribble DL, Farnier M, Macdonell G, Perevozskaya I, Davies MJ, Gumbiner B, Musliner TA.
    Metabolism; 2008 Jun 17; 57(6):796-801. PubMed ID: 18502262
    [Abstract] [Full Text] [Related]

  • 20. Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia.
    Goa KL, Barradell LB, Plosker GL.
    Drugs; 1996 Nov 17; 52(5):725-53. PubMed ID: 9118820
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.